Sucks to be in TR

Quote

anonymous

Guest
As Stanicky wrote to clients, many investors have been asking over the last week if a dramatic change is something Teva does in fact need—and whether enacting one is even possible. And while he didn’t lay out the case for a straight breakup, he did point out that selling the non-MS portion of the branded portfolio and pipeline—while hanging onto the blockbuster Copaxone franchise—could take out about two-thirds of Teva’s debt, “leaving a reasonably levered and more focused generic platform.”
 






anonymous said:
As Stanicky wrote to clients, many investors have been asking over the last week if a dramatic change is something Teva does in fact need—and whether enacting one is even possible. And while he didn’t lay out the case for a straight breakup, he did point out that selling the non-MS portion of the branded portfolio and pipeline—while hanging onto the blockbuster Copaxone franchise—could take out about two-thirds of Teva’s debt, “leaving a reasonably levered and more focused generic platform.”
Click to expand...

So these shit birds plan to sell everything off and leave the retained reps to twist in the wind by being let go by another company?
 






anonymous said:
So these shit birds plan to sell everything off and leave the retained reps to twist in the wind by being let go by another company?
Click to expand...

You figured that out all in your own! And the company purchasing the castoff divisions won't be as generous with the severance. You'll see. Everyone will be wishing they were part of last week's layoff.
 






Not too worried. Seems like wishful thinking by executives!

What company in there right mind would want to buy this division? For what exactly? ProAir (albuterol soon to be generic again), Qvar (generic soon), Qnasl (that's funny), Cinqair (possibly 500 patients nationwide).

The new respiclick devices will launch even worse than Proair did in that device. AB-rated Advair will be out in 17, and it can be automatically substituted.

They'd love to sell it, but no other company is dumb enough to willingly take on this shit show.
 






anonymous said:
Not too worried. Seems like wishful thinking by executives!

What company in there right mind would want to buy this division? For what exactly? ProAir (albuterol soon to be generic again), Qvar (generic soon), Qnasl (that's funny), Cinqair (possibly 500 patients nationwide).

The new respiclick devices will launch even worse than Proair did in that device. AB-rated Advair will be out in 17, and it can be automatically substituted.

They'd love to sell it, but no other company is dumb enough to willingly take on this shit show.
Click to expand...

And this is your rational for not being concerned? Lol. Either way this division is screwed! Nobody wanting to buy a division that has nothing going on is exactly why we are all in trouble! And last time I checked respiratory experience isn't exactly in high demand in the specialty pharmaceutical arena.
 


















Top Bottom
Back
Quote